Bladder cancer remains a major global health challenge, ranking as the tenth most common cancer overall and the sixth among men. Yet across geographies, the burden of disease looks very different, driven by a complex mix of environmental exposures, diagnostic...
Designing a clinical study has never been more complex—or more consequential. As protocols grow increasingly restrictive and timelines tighten, early design decisions can determine whether a study launches smoothly or struggles with amendments, delays, and...
When I think about the phrase “patient-centricity,” I often pause. It’s everywhere in our industry: clinical trial brochures, conference panels, even corporate mission statements. But too often, it risks becoming a buzzword rather than a lived reality. In our...
TriNetX is proud to announce that we were named a Best of Show Finalist at SCOPE, the summit for clinical ops executives, one of the industry’s premier events focused on advancing clinical operations and innovation. This recognition highlights our continued commitment...
As we step into 2026, the biopharma industry finds itself at a different starting line than anyone predicted just a year ago. As Director of Content & Communication at TriNetX, I’ve watched which resources captivated our community in 2025, and more...
When every respondent in a survey agrees, it’s more than a trend; it’s a mandate. In the 2025 TriNetX and studioID survey of 150 senior biopharma executives, all participants agreed that real-world evidence (RWE) has the potential to improve regulatory submissions....
